MONTREAL & SAN DIEGO--(BUSINESS WIRE)--Inversago Pharma Inc. (“Inversago”), a leader in the development of peripherally-acting CB1 receptor (CB1r) blockers to address complications associated with ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results